The Lancet· Shaodong Hong, Ting Zhou, Xue Hou, Xiangjiao Meng, Zhihuang Hu, Wei Zheng, Jiuwei Cui, Yongzhong Luo, Lin Wu, Meijuan Huang, Haipeng Xu, Jie Hu, Yanqiu Zhao, Wenxiu Yao, Yonggui Hong, Jun Cai, Yu Zhang, Chunxia Su, Conghua Xie, Ruoyu Wang, Xiang Li, Qiong He, Liang Zhang, Ruiling Ning, Daren Lin, Tongmei Zhang, Tienan Yi, Liqiang Zhong, Siyuan Huang, Hui Zhao, Jian Fang, Qing Bu, Bihui Li, Zhiye Zhang, Meiqi Shi, Jianhua Shi, Zhiping Deng, Yi Zhu, Hai Zhu, Sa Xiao, Lei Yang, Ni Song, Wenfeng Fang, Li Zhang, Yunpeng Yang, PANKU-Lung01 Investigators·· 5 小时前评分75
PANKU-Lung01三期：izalontamab brengitecan在第三代EGFR TKI治疗后EGFR突变晚期非鳞状NSCLC中较铂类化疗显著延长PFS
[Articles] Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China
导读
PANKU-Lung01三期试验显示，izalontamab brengitecan较铂类化疗显著延长EGFR突变晚期非鳞状NSCLC患者的PFS。研究纳入经第三代EGFR TKI治疗后进展的患者，3级及以上治疗相关不良事件发生率高于化疗。作者称，这些结果提供了双抗抗体偶联药物的首个三期证据，并支持izalontamab brengitecan作为该人群的潜在治疗选择。
来源：The Lancet · thelancet.com